Baseline | After 52-week use of CT-P13 | p value | |
---|---|---|---|
Age (years) | 69.5 (63–77) | ||
Gender (male/female), n (%) | 7 (25) / 21 (75) | ||
Body weight (kg) | 51.9 (46.6–58.4) | ||
Disease duration (years) | 18 (12.5–27) | ||
ACPA positive, % | 89 | ||
RF positive, % | 81 | ||
Steinbrocker class, (1/2/3/4) | 7/ 9/ 12/ 0 | ||
Use of MTX, n (%) | 28 (100) | 28 (100) | |
Dose of MTX (mg/week) | 6 (4–8) | 6 (4–8) | |
Use of corticosteroids, n (%) | 14 (50) | 14 (50) | |
Dose of corticosteroids (mg/day) | 2.5 (2.5–5) | 2.5 (2.5–5) | 0.33 |
Prior IFX treatment duration (months) | 109 (93.5–131.5) | ||
Prior IFX treatment dose (mg/kg) | 6.5 (4.5–8.9) | ||
Prior IFX treatment interval (weeks) | 8 (8–9) | ||
ESR (mm/h) | 22.5 (15.3–35.8) | 18.5 (8.8–29.8) | 0.06 |
CRP (mg/dL) | 0.1 (0.06–0.8) | 0.2 (0.07–0.8) | 0.93 |
MMP-3 (ng/ml) | 80.2 (39.1–138.7) | 66.8 (39.0–106.2) | 0.3 |
DAS28 | 2.9 (2.3–3.2) | 2.7 (1.9–3.1) | 0.23 |